Clinical Trials Logo

Filter by:
NCT ID: NCT05186181 Recruiting - Vascular Diseases Clinical Trials

Endovascular Repair With In Situ nEedle feNestration of Left Subclavian Artery to Treat AoRtic Dissection(RISEN STAR):A Multicenter Prospective Trial.

Start date: January 1, 2022
Phase:
Study type: Observational

Background: Aortic dissection (AD) is a common emergency in vascular surgery, which seriously threatens human life and health. The rupture of Stanford type B dissection is located in aortic arch and the dissection range is from the descending aorta or involves the abdominal aorta. At present, the endovascular repair of the thoracic aorta (TEVAR) for AD has been widely deployed worldwide and has become the standard surgical procedure for the treatment of AD. However, there is still controversy regarding the Stanford B aortic dissection that involves the left subclavian artery or the stent landing area less than 1.5 cm. Study objective: To evaluate the effectiveness and safety of endovascular repair with in situ needle fenestration of left subclavian artery. Methods: This study intends to enroll 217 patients with Stanford type B aortic dissection who meet the enrollment criteria. The patients will be followed up at 1, 6, 12, and 24 months after endovascular repair, and the CTA images of the thoracic aorta were collected.

NCT ID: NCT05186012 Recruiting - NHL, Adult Clinical Trials

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: June 14, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-1252 single agent and in combination with other therapeutic agent in patients with NHL.

NCT ID: NCT05184946 Recruiting - Gastric Cancer Clinical Trials

Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma

Start date: October 9, 2021
Phase: Phase 2
Study type: Interventional

To study the efficacy and safety of camrelizumab combined with SOX regimen for adjuvant therapy of stage III gastric cancer

NCT ID: NCT05184712 Recruiting - Clinical trials for Non-Squamous Non-small Cell Lung Cancer

Phase 3 Clinical Study of AK112 for NSCLC Patients

Start date: January 1, 2022
Phase: Phase 3
Study type: Interventional

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of Ivonescimab (SMT112 or AK112) or Placebo Plus Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)

NCT ID: NCT05184374 Recruiting - Clinical trials for Hypogonadotropic Hypogonadism

Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The Hypogonadotropic Hypogonadism(HH) could be caused by sellar lesions, sellar surgery or sellar radiotherapy. The incidence of HH after sellar surgery was higher in men than in women, and the therapy of HH was insufficient. Gonadotropin-releasing hormone(GnRH) stimulation test is used to evaluate the function of pituitary-gonadal axis. GnRH can be used to diagnose and treat fertility disorders and other endocrine disorders caused by HH. After a single injection of GnRH, the patients with poor response of luteinizing hormone and follicle stimulating hormone need to take extended provocation test, which is conducive to the formulation of the following treatment. GnRH pump can pulse subcutaneous injection of gonadorelin, which can be used as the extended provocation test.

NCT ID: NCT05184296 Recruiting - Septic Shock Clinical Trials

ExtraCorporeal Membrane Oxygenation in the Therapy for REfractory Septic Shock With Cardiac Function Under Estimated

ECMO-RESCUE
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The ECMO-RESCUE study is a prospective, multicenter, non-randomized, cohort study. In this study, we aimed to assessed whether VA-ECMO treatment can improve the 30-day survival rate of patients with sepsis-induced refractory cardiogenic shock.

NCT ID: NCT05184049 Recruiting - Diabetes Clinical Trials

Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients

Start date: January 2022
Phase: Phase 4
Study type: Interventional

This study evaluated the efficacy of epalrestat in diabetic peripheral neuropathy and its effects on the central nervous system in diabetic peripheral neuropathy subjects.

NCT ID: NCT05183438 Recruiting - Clinical trials for Metachronous Colorectal Adenoma

Construction of a Prediction Model for Metachronous Colorectal Adenoma

Start date: May 1, 2021
Phase:
Study type: Observational

The study aimed to explore the independent risk factors for the metachronous colorectal adenoma after endoscopic resection, and construct the prediction model of metachronous colorectal adenoma, in order to provide theoretical basis for postoperative follow-up time of patients, and allocate limited medical resources.

NCT ID: NCT05183425 Recruiting - Clinical trials for Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases

Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis

Start date: January 1, 2022
Phase:
Study type: Observational

Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver metastasis remains poor. Tumor heterogeneity is the cause of treatment failure. In this study, we aim the investigate the consistency of drug sensitivity for the matched primary and metastatic tumor in patients with liver metastasis.

NCT ID: NCT05183243 Recruiting - Colorectal Cancer Clinical Trials

Dose Finding Study of GH21 in Adult Patients With Advanced Solid Tumors

Start date: February 20, 2022
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.